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Abstract
Pancreatic cancer is one of the worst forms of cancer that can develop in an individual.Traditionally, chemotherapy
is administered but it has very limited success. Using the immune system to treat the cancer is very enticing and
many studies have been conducted to attempt to harness the body’s own mechanisms to defeat the cancer. It
seems that in order to properly treat the tumor a two pronged approach must be used. First, the immune system
must be stimulated to react to the tumor and attack it. A possible cytokine that can be utilized is interferon alpha,
which could result in a proliferation of T cells, but also appears to cause severe side effects. This can be overcome
by introducing the interferon virally. Second, immune suppression must be overcome.This can be accomplished by
using antibodies to destroy regulatory (CD-25) T cells that would ordinarily prevent a T cell response. However,
care must be taken to avoid inducing autoimmunity.
Introduction

Pancreatic cancer is one of the worst forms of cancer that can
develop in an individual. A growing tumor in the pancreas can
grow for fifteen years before it metastasizes, at which point it
becomes symptomatic. It is a silent killer growing inside the body.
Less than 1 % of patients diagnosed with pancreatic cancer survive even five years, with a median survival of four to six months
(Warshaw, Fernandez-del Castillo, 1992). Pancreatic cancer is resistant to traditional chemotherapy treatment and therefore even
once the cancer is detected, the treatment currently available to
patients is mildly effective at best (Michel, Gress, 2013).
Surgery, as well has proved only mildly effective. Researchers
found that less than 10% of patients survived five years after surgical removal of the tumors.This failure has been attributed to small
amounts of cells that are left behind that prove to be lethal. In fact,
28% of patients have been found to have circulating tumor cells in
the blood and the prevalence increased with the cancer stage (van
Heerden, et. al. 1981).This would indicate that surgery alone is not
effective and other treatments should be sought.
Recently, a new chemotherapy (FOLFIRINOX) was proposed
which showed promising signs, giving patients a longer survival
time than that associated with the traditional chemotherapies.
However that advantage didn’t translate into actually curing the
disease, just prolonging the patients’ lives by a few months. In addition, this drug showed an increased toxicity, which limited its use
to only the few patients that can tolerate it (Conroy, et. al. 2011).
It is therefore obvious that new approaches must be sought towards defeating this cancer. Prolonging the lives of its victims is
not an end goal. Rather, a way of ridding them of the disease altogether is required. It is therefore obvious that new approaches
must be sought. Recent research has shown promising results in
the field of immunology which could indicate some new treatment approaches geared towards eliminating this disease.

Adaptive immunological protection is provided to our bodies via
two pathways. B cells provide extracellular or humoral immunity
and create antibodies while T cells provide intracellular or cell
mediated immunity. Both of these pathways are crucial in order
for our bodies to be able to fight off even the “simplest” infections.
If these systems are compromised, even a common cold can prove
fatal as is evidenced by the HIV virus.
Innate immunity is provided by mechanical barriers such as skin
and epithelial linings and cellular protection by macrophages,
other phagocytes and natural killer cells. Macrophages phagocytose antigens into a phogosome and upon receiving signals provided by certain cytokines, kill the antigens that are engulfed by
combining the phagosome with a lysosome. The lysosome contains toxic chemicals that can degrade the antigens. Natural killer
cells respond to infected cells and destroy them before more cells
become infected.
Adaptive immunity is provided primarily by B cells and T cells. B
cells create a number of antigen receptors. Some of these receptors
can be secreted as antibodies and others are attached to the cell
surface and function as B cell antigen receptors. The first receptor
that the B cell creates is the IgM receptor, which is closely followed
by the IgD receptor. These receptors are very specific and can detect sequences of polysaccharides as well as peptide antigens and
respond to them. The B cells can then produce different antibodies
depending on the nature of the antigen in order to better combat it.
The other antibodies that they can produce are IgA, IgE, and IgG. IgA
is produced in response to mucosal infections and has the ability to
cross mucous membranes. IgE is primarily produced in response to
allergens and activates mast cells to release histamine. IgG is one of
the primary antibodies used to fight infection due to its utilization
of many mechanisms to assist in destruction of pathogens. It can
coat antigens (opsonization) in order to assist in their phagocytosis,
as well as directly neutralizing them by binding to their surface.

29

Yehuda Lehrfield

T cells are subdivided into helper T cells and cytotoxic T cells.
These cells are distinguished by certain biochemical markers on
their surface.The helper T cell has a CD-4 molecule on its surface,
while the cytotoxic T cell has a CD-8 molecule on its surface.
The CD-4 T cell is further subdivided into Th1 helper T cells and
Th2 helper T cells. The Th1 helper T cell is supportive of a CD-8
cytotoxic response and help the cytotoxic T cells lyse infected
cells. However the Th2 helper T cell is not supportive of a CD-8
cytotoxic response and promotes immune suppression. All T cells
can only recognize antigen by their T cell receptors if the antigen
is presented by other cells via a molecule called MHC (Major
Histocompatibility Complex) which is present on the other cells.
Certain cells are specialized towards presenting antigen to the T
cells.This is accomplished by the cell engulfing the foreign material
(phagocytosis), degrading it and presenting peptide fragments to
the T cell.The cells that are specialized towards presenting antigen
are known as antigen presenting cells.These can be dendritic cells,
B cells and macrophages. Dendritic cells are especially proficient
at antigen presentation therefore, the presence of mature dendritic cells is important in order to present the antigen to the T cells.
The CD-4 helper T cells recognize antigen presented via MHC
class II which is primarily found only on these specialized antigen
presenting cells. On the other hand, the CD-8 cytotoxic T cells
recognize antigen presented by MHC class I which is present on
almost all cells of the body.

if the T cell is recognizing antigen, the T cell is prevented from
mounting a response (Abbas, et. al. 2012).

The amazing thing about the immune system is its diversity.
Because of the various genes that code for the T cell receptors,
the amount of combinations that the T cell can use is astronomical. Therefore, not only can the receptors be incredibly specific,
but there can also be a tremendous amount of diversity. The big
problem that the T cells and the B cells face is how to “know”
how to react to foreign antigen and not react to self-antigen and
cause autoimmunity. Autoimmunity is when the immune system
targets and starts killing the body’s own cells. The way that the
body solves this problem is by negative selection. This consists
of a rigorous test that T cells undergo in the Thymus and B cells
undergo in the bone marrow during development. The cells are
exposed to self-antigen. If they recognize self-antigen with high
affinity they undergo apoptosis and are not permitted to mature.
If however they recognize self-antigen with only low affinity, they
are permitted to mature and perform their function.

Samples of pancreatic tumors from 80 surgically resected tumors
were studied for signs of immune cell presence, particularly CD-4
and CD-8 T- cells. Some patients had one and not the other while
some had both or none. They noticed that from the patients that
had both CD-8 and CD-4 T cell infiltration, the overall survival
rate was much higher than those that were missing one or both of
these cells. In addition it was apparent that the depth to which the
cancerous cells were able to penetrate in the pancreas was much
less for those patients with high levels of both CD-4 and CD-8
T cells. It would seem that the presence of the T cells indicates
that the T cells are suppressing the cancerous cells and preventing
them from infiltrating further.The researchers thus concluded that
a high level of T cells in the affected pancreas positively correlates
to an increased survival rate (Fukunaga, et. al. 2004).

In addition to regulation at the T cell and B cell development stage,
there are certain helper T cells that ensure that T cells do not
react to self-antigen. These are known as regulatory T cells and
help shut down the T cell response at the end of an adaptive immune response and also ensure that T cells that escaped negative
selection in the Thymus can be prevented from attacking healthy
tissue and causing auto-immunity. There are also receptors on the
T cells themselves that prevent auto-immunity. One of the primary receptors is the CTLA-4 receptor. When it is engaged, even
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It has been thought since the 1950s that one of the functions of
the immune system is to prevent the occurrence of cancer in the
body. This theory is known as immune surveillance. This theory is
supported by the high incidence of cancer in immune-compromised hosts such as patients with HIV and AIDS (Goedert, et. al.
1998) as well a high incidence of tumor formation among patients
taking immunosuppressive medications (Sanchez, et. al. 2002). This
would indicate that there is some role in the prevention of tumors by the immune system. It has therefore been assumed that
there must be some antigens that cancerous cells express that are
recognized by the immune system. In fact many tumor antigens
have been identified. In some cases the antigens are normal proteins that are usually only present during a particular stage of the
cell’s life but, because of the tumor are now present during other
stages as well. They can also be normal proteins that are merely
over expressed in the cancer cells. Other antigens that have been
identified are mutated proteins that are present in the diseased
cell. However, due to the fact that even immune-competent hosts
have developed cancer, it would seem that the immune system is
not highly adept at fighting these tumors. Can the immune system
be induced to fight against pancreatic cancer?

Discussion

What can be used to attract the T cells? Pancreatic cancer patients
treated with Interferon alpha after undergoing surgery to remove
part of the pancreas were studied. Interferon alpha is a cytokine
produced by the body and is used in the immune response to
infected cells. When a cell is infected it produces various cytokines that cause downstream signaling. This downstream signaling
refers to signals that the antigen presenting cells receive by these
cytokines and increase the antigen presentation to the T cells.This
is an obvious benefit because additional antigen presentation will
lead to an increased T cell response. Introducing Interferon alpha
in addition to the standard chemotherapy increased the length of

Immunological treatment for pancreatic cancer

the side effects. A recent study of 28 pancreatic cancer patients
undergoing this treatment showed an increase in toxicity resulting
in a decrease in white blood cells (leukopenia) and a decrease
in neutrophils (neutropenia). Although the toxicity was reversible
and no patients died, an important consideration is the effect the
medication has on overall quality of life. The study found that although the overall quality of life decreased, it wasn’t a significantly
larger decrease than those patients being treated with the standard chemotherapy. However, it is noteworthy that some of the
patients being treated with this therapy needed to be hospitalized
with vomiting, abdominal pain and dehydration (Katz, et. al. 2011).

Table 1:
Survival statistics of patients undergoing interferon alpha therapy (Picozzi, et.
al. 2003).

survival for pancreatic cancer patients. 88% percent of patients
undergoing the interferon therapy were still alive after two years
and 55% survived to the five year mark (Tables 1 and 2). This is
a significant increase as the normal 2 year rate of survival for
patients being treated with standard chemotherapy alone is 40%.
The theory is that as interferon is introduced, tumor antigen presentation is upregulated and therefore more T cells can infiltrate
the area and fight the cancer. The study noted however that further research was still needed (Picozzi, et. al. 2003).
However this study was conducted using patients that had already
had surgery. Only 20% of pancreatic cancer patients have operable
tumors and therefore it is apparent that other methods must be
sought out as well.
Some big drawbacks of using interferon-based chemotherapy are

In response to this systemic toxicity, scientists have proposed
infecting cancer cells with adenoviruses that express Interferon
alpha in order to restrict the effects of the interferon localy rather
than systemically. In studies of other cancers, viruses have been
shown to exhibit promising effects. The virus can be induced to
specifically target cancer cells and not healthy cells by using a
tumor specific promoter called cyclooxygenase 2 which is over
expressed in cancerous cells. In the case of the adenovirus proposed treatment for pancreatic cancer, after the virally infected
cell goes through its replication cycle in the infected host cell,
it produces a “death protein” causing cell death so as to release
viral particles and infect neighboring cells (Kuruppu,Tanabe, 2005).
Although previously pancreatic cancer has shown resistance to
adenoviruses, that has been attributed to a lack of coxsackie-adenovirus receptors on the cell surface. The newly developed adenovirus has been coaxed to bind to alternate cell surface receptors namely arginine-glycine-aspartic fiber and Ad3 receptor.
When the virally infected cell dies it releases interferon and can
thus be contained locally and not cause widespread toxicity and
dangerous side effects. This treatment thus combats the cancer in
two ways. The virus itself kills cancerous cells, and the interferon

Table 2:
Survival outcomes for pancreatic cancer patients undergoing various treatments (Picozzi, et. al. 2003).
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that is released induces immunological resistance to the tumor. (
Armstrong, et. al. 2012).
There is another problem that must be dealt with in treating any
cancer using immunotherapy; the problem of immunosuppression.
As the tumor grows, it changes the local environment from one of
immunogenicity (favorable to destruction by the immune system)
to one of immunotolerance (unfavorable to destruction by the
immune system).As mentioned earlier, CD-8 and CD-4 Th1 T cells
are extremely important in proper immune function. However as
the disease progresses there is a larger presence of Th2 T cells, ineffective CD-8 T cells and perhaps most significantly, an increase in
regulatory T cells which aid in immune suppression by expressing
CTLA-4 receptors and secreting immunosuppressive cytokines
like TGF-β, IL-4 and IL-5 (Ikemoto, et. al. 2006). There is also an
increase in myeloid derived suppressor cells. These cells suppress
both the innate and the adaptive immune response (Gabitass,

et. al. 2011). In addition, rather than there being an infiltration
of M1 - classically activated macrophages - which phagocytose
and destroy antigens, there is an infiltration of M2 macrophages
which are associated with tissue repair. They therefore remodel
the matrix and in fact enhance the tumor and assist in its growth
(Schmeider, et. al. 2012) (figure 1).
Therefore, to truly mount an immunological assault on the cancer,
these obstacles must be overcome. A way must be found in which
to cause an infiltration of Th1 helper T cells, classically activated macrophages and a decrease in the number of regulatory T
cells and myeloid derived supressor cells in the area of the tumor.
Recent research has been exploring possible options.
Using antibodies that specifically target the CD-25 marker on
regulatory T cells, researchers depleted a splenic cell suspension
containing T cells, of the regulatory T cells within. They injected

Figure 1.
Changes in the tumor microenvironment during cancer growth (Sideras, et. al. 2014)
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nude mice (a strain of mice that due to a genetic mutation have no
thymus and therefore have no T cells), with this sample and later
with leukemia. They noticed that the tumors first grew and then
regressed in most of the mice, allowing the mice to live long term
(more than 80 months). Most of the mice that were injected with
a non-depleted splenic cell suspension died of the tumor within
40 days. Furthermore, when the mice were reinjected with larger
doses of leukemia the immune system mounted an even stronger response and rejected the leukemia much more vigorously.
This indicated that the mice had become immune to the cancer.
The conclusion of the researchers was that regulatory T cells prevent other T cells from mounting an immune response. They also
injected ordinary mice with anti CD-25 antibody and leukemia
suspensions. These tumors also grew and then regressed within
1 month in more than 90% of the mice whereas all the control
mice, injected with ordinary antibodies (not specific to CD-25),
died within 1 month indicating that even normal mice were able
to mount a response once the regulatory T cells were depleted
(Shimizu, et. al. 1999).
It seems that depletion of the CD-25 T cells allows activated, anti-tumor CD-8 and CD-4 T cells to infiltrate and kill the tumor. In
a clinical trial of breast cancer patients treated with Daclizumab, a
drug containing anti CD-25 antibodies along with an anti-cancer
vaccine a marked decrease in CD-25 T cells was observed (Rech,
Vonderheide, 2009). However at the time of this report only three
patients were analyzed, and it is therefore premature to declare
this treatment a success. In addition, Dr. Vonderheide, one of the
researchers in this clinical trial, declared a potential conflict of
interest due to his involvement in developing the included cancer
vaccine administered along with the Daclizumab. More research
on pancreatic cancer as well as other cancer patients still needs
to be conducted before this treatment can be assumed to be
effective.
However, regulatory T cells have been associated with prevention
of autoimmunity. Previously, in studies done where T cells were
removed, autoimmunity was generated. It was, however, unclear
whether removing T cells caused autoimmunity because of a lack
of regulatory T cells or because of a profound lack of any T cells
which then allowed microbial infections to occur. Recently, however a study was conducted in which specifically regulatory T cells
were removed from mice. Autoimmunity soon developed in various forms such as diabetes, thyroiditis, and autoimmune gastritis
(Sakaguchi, et. al. 2001). Any treatment that attempts to eliminate
regulatory T cells should therefore try to limit the treatment locally to the site of the tumor or cancerous cells in order to prevent autoimmunity in other parts of the body.

Conclusion

Although pancreatic cancer is one of the most difficult cancers
to treat, a multi-pronged approach to treating this disease immunologically would perhaps lengthen the survival time and maybe
even cure this disease. A possible approach to treating this disease
could include interferon alpha alone, or virally, in combination with
anti CD-25 antibodies. This would attract T cells to the site of the
cancer while at the same time limiting the amount of regulatory
T cells that ordinarily prevent an anti-cancer response. Care must
be taken however, to ensure patients do not suffer significant loss
of quality of life. In addition a balance must be struck between
eliminating regulatory T cells while still avoiding autoimmunity.
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